{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:50:43Z","timestamp":1782737443107,"version":"3.54.5"},"reference-count":17,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Introduction: Oligometastatic prostate cancer represents an intermediate disease state potentially amenable to metastasis-directed therapies such as stereotactic body radiotherapy (SBRT), aiming to delay disease progression and postpone systemic treatment. Aim: The aim of this study was to evaluate the real-world outcomes of SBRT in patients with hormone-sensitive oligometastatic prostate cancer.\nMethods: This single-center retrospective study included patients with hormone-sensitive oligometastatic prostate cancer staged with PSMA PET and treated with SBRT at a tertiary center between January 2022 and March 2024. The primary endpoint was hormone therapy-free survival (HTFS). Secondary endpoints included event-free survival (EFS), local control, overall survival (OS), and toxicity.\nResults: A total of 34 patients were included, predominantly with low-volume disease (79.4% with a single metastasis). SBRT achieved significant biochemical responses (PSA50 in 69.7%; median PSA nadir 0.19 ng\/mL). HTFS rates were 85.2% and 74.6% at 12 and 24 months, respectively, with the median not reached. Median EFS was 16.2 months. Local control was 84.2%, and 24-month OS was 87.8%. Toxicity was minimal, with no grade \u2265 3 adverse events. A PSA nadir \u2264 0.20 ng\/mL and ISUP \u2264 2 were associated with improved outcomes.\nConclusions: SBRT may delay systemic therapy without compromising disease control in oligometastatic prostate cancer. Its integration into personalized treatment strategies, guided by biological and biochemical factors, represents a promising therapeutic approach.<\/jats:p>","DOI":"10.4081\/aiua.2026.15530","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:05:58Z","timestamp":1780041958000},"source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic radiotherapy in oligometastatic prostate cancer: a single-center experience"],"prefix":"10.4081","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-8518","authenticated-orcid":false,"given":"Ana Marta","family":"Ferreira","sequence":"first","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Cunha","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Tavares da Silva","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra; Faculty of Medicine, University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Nunes","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra; Faculty of Medicine, University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Urology and Renal Transplantation Department, Centro Hospitalar e Universit\u00e1rio de Coimbra; Faculty of Medicine, University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"232699","unstructured":"1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2022. CA Cancer J Clin. 2024; 74:33-52."},{"key":"232700","doi-asserted-by":"crossref","unstructured":"2. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89.","DOI":"10.14740\/wjon1191"},{"key":"232701","doi-asserted-by":"crossref","unstructured":"3. Kirby M, Hirst C, Crawford ED. Castration-resistant prostate cancer. Int J Clin Pract. 2011; 65:1180-1192.","DOI":"10.1111\/j.1742-1241.2011.02799.x"},{"key":"232702","doi-asserted-by":"crossref","unstructured":"4. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer (proPSMA). Lancet. 2020; 395:1208-1216.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"232703","doi-asserted-by":"crossref","unstructured":"5. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13:8-10.","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"232704","doi-asserted-by":"crossref","unstructured":"6. Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy in oligometastatic prostate cancer. Eur Urol.2015; 67:852-863.","DOI":"10.1016\/j.eururo.2014.09.004"},{"key":"232705","doi-asserted-by":"crossref","unstructured":"7. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease. Lancet Oncol. 2020; 21:e18-e28.","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"232706","doi-asserted-by":"crossref","unstructured":"8. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: APCCC 2019. Eur Urol.2020;77:508-547.","DOI":"10.1016\/j.eururo.2020.01.012"},{"key":"232707","doi-asserted-by":"crossref","unstructured":"9. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013; 14:e28-e37.","DOI":"10.1016\/S1470-2045(12)70510-7"},{"key":"232708","doi-asserted-by":"crossref","unstructured":"10. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): a randomized phase II trial. J Clin Oncol. 2018; 36:446-453.","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"232709","doi-asserted-by":"crossref","unstructured":"11. Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). JAMA Oncol. 2020; 6(5):650-659.","DOI":"10.1001\/jamaoncol.2020.0147"},{"key":"232710","unstructured":"12. Franzese C, Comito T, Clerici E, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer. Clin Oncol (R Coll Radiol). 2021; 33:e284-e292."},{"key":"232711","unstructured":"13. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2024."},{"key":"232712","unstructured":"14. Tran PT, et al. Stereotactic ablative radiotherapy for oligometastatic prostate cancer: patterns of failure. Int J Radiat Oncol Biol Phys. 2018; 102:1304-1310."},{"key":"232713","doi-asserted-by":"crossref","unstructured":"15. Decaestecker K, De Meerleer G, et al. Repeated stereotactic body radiotherapy for oligometastatic recurrence. Eur Urol. 2014; 66:45-53.","DOI":"10.1186\/1748-717X-9-135"},{"key":"232714","doi-asserted-by":"crossref","unstructured":"16. Palma DA, Olson R, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers (SABRCOMET). Lancet. 2019; 393:2051-2058.","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"232715","doi-asserted-by":"crossref","unstructured":"17. Marvaso G, Corrao G, Zaffaroni M, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025; 26:300-311.","DOI":"10.1016\/S1470-2045(24)00730-7"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/15530\/14119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/download\/15530\/14119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:43:35Z","timestamp":1782737015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/aiua\/article\/view\/15530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2026.15530","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}